Zobrazeno 1 - 10
of 41
pro vyhledávání: '"pharmacoeconomic studies"'
Autor:
I. S. Datsenko, A. V. Kabachna
Publikováno v:
Фармацевтичний журнал, Vol 4, Pp 31-41 (2022)
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that causes the blood vessels in the lungs to thicken and narrow, forcing the heart to pump blood through the lungs at high pressure. In recent years, a significant nu
Externí odkaz:
https://doaj.org/article/47a31278db1b4b8a914113aec971e958
Publikováno v:
Hospital Pharmacology, Vol 8, Iss 1, Pp 998-1003 (2021)
Introduction: Key problems when transferring results of pharmacoeconomic studies between countries are: relative infrequency of observational design, utilization of unreliable estimates of input parameters in many of modelling studies, not reporting
Externí odkaz:
https://doaj.org/article/ad63c9dbdb5c4be693ddabe704f988b4
Autor:
A. U. Kulikov, V. V. Babiy
Publikováno v:
Фармакоэкономика, Vol 6, Iss 4, Pp 53-58 (2015)
approximately 5-7% of people in Russia have diabetes. In addition, the number is growing every year. Diabetes treatment schemes mostly focused on normalizing the blood glucose level. To achieve it patients use the glucose meters. However, there are s
Externí odkaz:
https://doaj.org/article/28bafe054ded4e3895f28e15159bb057
Publikováno v:
Фармакоэкономика, Vol 7, Iss 1, Pp 22-26 (2015)
Concomitant correction of magnesium deficiency in children with uncontrolled asthma can improve the efficiency of basic therapy for achieving asthma control and possesses pharmacoeconomic benefits, reducing the cost of achieving control and cost per
Externí odkaz:
https://doaj.org/article/2f96403aaff342d9bc6a1fd50d7bc00a
Autor:
A. Yu. Kulikov, V. G. Serpik
Publikováno v:
Фармакоэкономика, Vol 6, Iss 2, Pp 15-19 (2015)
Pharmacoeconomic study of treatment primary open-angle glaucoma with carbonic anhydrise inhibitors by mean of costefficacy and budget impact analysis. Results have shown, that Azopt has benefits compare with Dorzopt and Trusopt from cost-efficacy per
Externí odkaz:
https://doaj.org/article/7aee7170c903471fa826ea0de8994f06
Autor:
A. Yu. Kulikov, V. G. Serpikov
Publikováno v:
Фармакоэкономика, Vol 5, Iss 2, Pp 28-32 (2015)
pharmacoeconomic study of treatment primary open-angle glaucoma with combinations of prostaglandin analogues and beta-blockers by mean of cost-efficacy and budget impact analysis. Results have shown, that Duotrav (travoprost+timolol) has benefits com
Externí odkaz:
https://doaj.org/article/83a2c9fa8cb343e2959b816f4667f9bd
Autor:
M. V. Protsenko
Publikováno v:
Фармакоэкономика, Vol 5, Iss 3, Pp 27-32 (2015)
Abstract: pharmacoeconomic study of treatment primary open-angle glaucoma with fix combination of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost minimization and budget impact analysis was conducted.
Externí odkaz:
https://doaj.org/article/a2fa8bb3bc4e4fdea9c7fa08009073fe
Publikováno v:
Hospital Pharmacology-International Multidisciplinary Journal (2021) 8(1):998-1003
Hospital Pharmacology, Vol 8, Iss 1, Pp 998-1003 (2021)
Hospital Pharmacology, Vol 8, Iss 1, Pp 998-1003 (2021)
Introduction: Key problems when transferring results of pharmacoeconomic studies between countries are: relative infrequency of observational design, utilization of unreliable estimates of input parameters in many of modelling studies, not reporting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e4b6cfcd59810694f88cc1293225ae
http://scindeks.ceon.rs/article.aspx?artid=2334-94922101998J
http://scindeks.ceon.rs/article.aspx?artid=2334-94922101998J
Publikováno v:
Вестник Волгоградского государственного медицинского университета.
Стартовая терапия флутиказона пропионатом (100 мкг/сут) у детей до 5 лет с неконтролируемой астмой обладает экономическими преимуществам
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2806::e7838566ffae8f956be966b981161aca
http://cyberleninka.ru/article/n/farmakoekonomicheskoe-obosnovanie-vybora-startovoy-terapii-nekontroliruemoy-bronhialnoy-astmy-u-detey-rannego-vozrasta
http://cyberleninka.ru/article/n/farmakoekonomicheskoe-obosnovanie-vybora-startovoy-terapii-nekontroliruemoy-bronhialnoy-astmy-u-detey-rannego-vozrasta
Autor:
Celik, Yusuf, Seiter, Andreas
Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2456::06327e4f8ce033e197baf2ca86f0e845
https://hdl.handle.net/10986/28110
https://hdl.handle.net/10986/28110
